Oxford Gene Technology (OGT) has expanded its Cytocell sarcoma fluorescence in situ hybridisation (FISH) probe range with three new products.
While the first two products FUS Breakapart, FOXO1 Breakapart carry the CE-IVD label the third probe, TFE3 Breakapart is only for research purposes only, the company stated.
The company said the products have been developed in response to the genes of FUS and FOXO1 which are both implicated in various weakness causing neoplastic diseases.
It has also been reported that FUS gene can recurrently rearrange with a number of different partner genes in several types of neoplastic diseases, notably soft tissue sarcomas and acute myeloid leukaemia.
Translocations involving the FOXO1 gene are associated with about 80% cases of alveolar rhabdomyosarcoma.
OGT Pathology senior product manager Steve Chatters said: “These new probes clearly show OGT’s commitment to being a market leader for high-quality FISH probes in the fast-moving field of cancer research; with over 20 new FISH probes released in the last year, Cytocell’s FISH portfolio is second-to-none in both range and quality.
“We are committed to keeping up with our customers’ expectations by further expanding the Cytocell cancer FISH probe range in 2017.”
The company claims that due to their specificity, Cytocell Aquarius FISH probes can give out high-intensity signals with minimal background fluorescence.